0000000000240749

AUTHOR

Hans Christiansen

showing 9 related works from this author

Fractionated External Beam Radiotherapy as a Suitable Preparative Regimen for Hepatocyte Transplantation After Partial Hepatectomy

2010

Purpose Hepatocyte transplantation is strongly considered to be a promising option to correct chronic liver failure through repopulation of the diseased organ. We already reported on extensive liver repopulation by hepatocytes transplanted into rats preconditioned with 25-Gy single dose selective external beam irradiation (IR). Herein, we tested lower radiation doses and fractionated protocols, which would be applicable in clinical use. Methods and Material Livers of dipeptidylpeptidase IV (DPPIV)-deficient rats were preconditioned with partial liver external beam single dose IR at 25 Gy, 8 Gy, or 5 Gy, or fractionated IR at 5 × 5 Gy or 5 × 2 Gy. Four days after completion of IR, a partial …

Cancer ResearchTransplantation ConditioningDipeptidyl Peptidase 4medicine.medical_treatmentmedicineAnimalsHepatectomyRadiology Nuclear Medicine and imagingExternal beam radiotherapyPreparative RegimenRadiationbusiness.industryDose fractionationRatsRadiation therapyTransplantationmedicine.anatomical_structureLiverOncologyHepatocyteHepatocytesDose Fractionation RadiationTransplantation ConditioningHepatectomyNuclear medicinebusinessBiomarkersInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

External-beam radiotherapy as preparative regimen for hepatocyte transplantation after partial hepatectomy

2006

Purpose: The transplantation of donor hepatocytes is considered a promising option to correct chronic liver failure through repopulation of the diseased organ. This study describes a novel selective external-beam irradiation technique as a preparative regimen for hepatocyte transplantation. Methods and Materials: Livers of dipeptidylpeptidase IV (DPPIV)–deficient rats were preconditioned with external-beam single-dose irradiation (25 Gy) delivered to two thirds of the liver. Four days later, a one-third partial hepatectomy (PH) was performed to resect the untreated liver section, and 15 million wild-type (DPPIV + ) hepatocytes were transplanted via the spleen into the recipient livers. The …

Cancer ResearchPathologymedicine.medical_specialtyTransplantation ConditioningDipeptidyl Peptidase 4medicine.medical_treatmentSpleenmedicineAnimalsHepatectomyRadiology Nuclear Medicine and imagingExternal beam radiotherapyDipeptidyl peptidase-4Cell ProliferationPreparative RegimenRadiationbusiness.industryRats Inbred F344RatsTransplantationRadiation therapymedicine.anatomical_structureLiverOncologyHepatocyteChronic DiseaseHepatocytesFemaleHepatectomybusinessLiver FailureInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

A Putatively Functional Haplotype in the Gene Encoding Transforming Growth Factor Beta-1 as a Potential Biomarker for Radiosensitivity

2011

Purpose To determine whether genetic variability in TGFB1 is related to circulating transforming growth factor-β1 (TGF-β1) plasma concentrations after radiotherapy and to radiosensitivity of lymphoid cells. Patients and Methods Transforming growth factor-β1 plasma concentrations ( n = 79) were measured in patients 1 year after radiotherapy and chromosomal aberrations ( n = 71) ex vivo before therapy start. Furthermore, TGF-β1 secretion and apoptosis were measured in isolated peripheral blood mononuclear cells of 55 healthy volunteers. These phenotypes were analyzed in relation to five germline polymorphisms in the 5′ region of the TGFB1 gene. Because of high linkage disequilibrium, these fi…

AdultMaleCancer ResearchSomatic cellDNA damageApoptosisPolymorphism Single NucleotideRadiation TolerancePeripheral blood mononuclear cellLinkage DisequilibriumCell LineTransforming Growth Factor beta103 medical and health sciences0302 clinical medicineHumansMedicineRadiology Nuclear Medicine and imagingRadiosensitivityGeneMicronuclei Chromosome-DefectiveAged030304 developmental biologyAged 80 and over0303 health sciencesRadiationbiologybusiness.industryHaplotypeTransforming growth factor betaMiddle AgedMolecular biology3. Good healthHaplotypesOncology030220 oncology & carcinogenesisMicronucleus testImmunologyLeukocytes Mononuclearbiology.proteinFemalebusinessBiomarkersDNA DamageInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells

2007

To test the combined effects of oxaliplatin and radiation versus cisplatin and radiation using human cervical and lung cancer cell lines.CaSki cervical cancer cells, and A549 lung cancer cells were cultured under standard conditions. Cells were treated with escalating doses of gamma-irradiation (0-6 Gy), and with oxali- and cisplatin for 2 h or 24 h, or a combination of both. Cell survival was measured by a colony-forming assay. Survival curves were fitted to the data using the linear quadratic model. Sensitizer enhancement ratios (SER) were calculated at the 37% survival level, and isobologram analysis was applied to test for the drug-radiation interactions.Oxaliplatin as well as cisplatin…

OncologyRadiation-Sensitizing Agentsmedicine.medical_specialtyLung NeoplasmsOrganoplatinum Compoundsmedicine.medical_treatmentUterine Cervical NeoplasmsAntineoplastic Agents03 medical and health sciences0302 clinical medicineInternal medicineTumor Cells CulturedmedicineHumansCytotoxic T cellRadiology Nuclear Medicine and imagingLung cancer030304 developmental biologyCisplatinA549 cellCervical cancer0303 health sciencesDose-Response Relationship DrugRadiological and Ultrasound Technologybusiness.industryDose-Response Relationship Radiationmedicine.diseaseCombined Modality Therapy3. Good healthOxaliplatinOxaliplatinRadiation therapy030220 oncology & carcinogenesisToxicityFemaleCisplatinbusinessmedicine.drugInternational Journal of Radiation Biology
researchProduct

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study

2008

Abstract Background Recent studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-α (IFN-α) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods Eleven patients with histological diagnosis of localized carcinoma of the pancreas ( n  = 7) or periampullary ( n  = 4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three …

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentAntineoplastic AgentsRisk AssessmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicinePeriampullary cancerHumansNeoplasm InvasivenessRadiology Nuclear Medicine and imagingSurvival rateNeoplasm Staging030304 developmental biology0303 health sciencesbusiness.industryPatient SelectionRadiotherapy Dosagemedicine.diseaseCombined Modality Therapypeople.cause_of_deathRecombinant Proteins3. Good healthSurgeryPancreatic NeoplasmsSurvival RateRadiation therapyOncology030220 oncology & carcinogenesisConcomitantInterferon Type IFeasibility StudiesFemaleFluorouracilImmunotherapyCisplatinbusinesspeopleChemoradiotherapyProgressive diseaseCancer/Radiothérapie
researchProduct

Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study

2011

Abstract Background and purpose Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Materials and methods Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m2 per day and increased by s…

Oncologymedicine.medical_specialtyCancer ResearchRadiation-Sensitizing AgentsLung Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsNSCLCMedicine & Public Health; Hematology; Oncology; Internal Medicine; Cancer Research03 medical and health sciencesFludarabine0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineCombined Modality TherapyHumansConcurrent fludarabine and radiotherapy030304 developmental biologyNeoplasm Staging0303 health sciencesOriginal PaperHematologyNucleoside analoguebusiness.industryRadiotherapy DosageGeneral MedicineAdenine nucleosideRadiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCNucleoside analoguemedicine.diseaseCombined Modality Therapy3. Good healthFludarabinerespiratory tract diseasesClinical trialRadiation therapyOncology030220 oncology & carcinogenesisRadiotherapy phase I studybusinessFludarabine; NSCLC; Nucleoside analogue; Concurrent fludarabine and radiotherapy; Radiotherapy phase I study; Radiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCVidarabinemedicine.drug
researchProduct

The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.

2008

Despite proven antitumor activity of gemcitabine in chemoradiotherapy of advanced head and neck cancer, many authors refer to severe acute and late local and haematological toxicity. Fludarabine does imply nearly the same mechanisms of action as gemcitabine, inhibiting various enzymes involved in DNA replication. This investigation focuses on the combined effect of either fludarabine or gemcitabine and radiation on human squamous carcinoma cell lines in vitro, providing data for future decisions on head and neck chemoradiotherapy regimen.ZMK-1, A549, BW-225, GR-145, OH-65 and CaSki cell lines were incubated with either drug at defined schedules and irradiated at a single fraction dose of 2 …

Oncologymedicine.medical_specialtyRadiation-Sensitizing AgentsCell SurvivalApoptosisDeoxycytidine03 medical and health sciences0302 clinical medicineFludarabine monophosphateInternal medicineCell Line TumormedicineCarcinomaHumansRadiology Nuclear Medicine and imaging030304 developmental biology0303 health sciencesRadiological and Ultrasound Technologybusiness.industryHead and neck cancermedicine.diseaseGemcitabineGemcitabine3. Good healthFludarabineSquamous carcinomaApoptosis030220 oncology & carcinogenesisCarcinoma Squamous CellbusinessVidarabine PhosphateChemoradiotherapymedicine.drugInternational journal of radiation biology
researchProduct

Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?

2006

Histopathological tumor regression grade (TRG) has been shown to be a prognostic factor in patients with esophageal cancer after neoadjuvant radiochemotherapy (RCT). The system introduced by Mandard to group TRG (Cancer 1994;73:2680-2686) has been used to analyse and discuss its prognostic significance on survival in a single institution retrospective analysis: TRG 1 (complete regression) - TRG 5 (absence of regressive changes). Sixty patients with locally advanced (T3/4 or N1) adenocarcinoma or squamous cell carcinoma received cisplatin-based RCT. Three to four weeks later operation for curative intent was performed. Median follow-up was 17.7 months. Histopathological tumor stages were sta…

MaleOncologymedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatment03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaHumansMedicineGrading (tumors)Survival analysisNeoadjuvant therapyNeoplasm StagingRetrospective StudiesTumor Regression GradeUnivariate analysisbusiness.industryGastroenterologyGeneral MedicineMiddle AgedEsophageal cancerPrognosismedicine.diseaseSurvival AnalysisNeoadjuvant Therapy3. Good health030220 oncology & carcinogenesisAdenocarcinomaFemale030211 gastroenterology & hepatologybusinessFollow-Up StudiesDiseases of the Esophagus
researchProduct